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Manipulation of cell cycle is a commonly employed strategy of viruses for achieving
a favorable cellular environment during infection. Kaposi’s sarcoma-associated
herpesvirus (KSHV), the primary etiological agent of several human malignancies
including Kaposi’s sarcoma, and primary effusion lymphoma, encodes several
oncoproteins that deregulate normal physiology of cell cycle machinery to persist
with endothelial cells and B cells and subsequently establish a latent infection. During
latency, only a small subset of viral proteins is expressed. Latency-associated nuclear
antigen (LANA) is one of the latent antigens shown to be essential for transformation
of endothelial cells in vitro. It has been well demonstrated that LANA is critical
for the maintenance of latency, episome DNA replication, segregation and gene
transcription. In this review, we summarize recent studies and address how LANA
functions as an oncoprotein to steer host cell cycle-related events including proliferation
and apoptosis by interacting with various cellular and viral factors, and highlight the
potential therapeutic strategy of disrupting LANA-dependent signaling as targets in
KSHV-associated cancers.
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INTRODUCTION
The eukaryotic cell cycle is divided into four phases: G1, S, G2, and M. The G1 phase is the first
gap for cells to organize themselves prior to DNA replication. Any decisive events during G1 phase
will determine whether the cell continues to proceed for division, pauses, or exits the cell cycle and
enters the cell apoptosis pathway. The S phase is the stage for DNA synthesis, and hence genome
duplication. The G2 phase is the second gap for cells to prepare the process of mitosis, and the
associated cell division of two daughter cells, when the duplicated chromosomes are segregated
into separated nuclei and cytokinesis. In addition, G2 phase also provides an opportunity for
recognition and repair of damaged DNA. Thus, the G1 and G2 phase are called checkpoints for
DNA replication and mitosis during cell cycle, respectively (Gabrielli et al., 2012). Strict regulation
of cell division is critical for the normal development and maintenance of multicellular organisms.
Loss of control of cell division will ultimately lead to cancer (Kastan and Bartek, 2004). In the
past three decades, the studies of basic mechanism of cell cycle have led to a better understanding
of how the molecular events required for cell division are controlled and coordinated (Gabrielli
et al., 2012). The key elements in the basis of cell cycle regulation are the periodic synthesis and
destruction of cyclins, which associate with or activate cyclin-dependent kinases (Cdks) (Dai and
Grant, 2011). Although at least 16 cyclins and 9 Cdks have been identified in mammalian cells, not
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all cyclins and Cdks is necessary to regulate the cell cycle, some
have been shown act as regulators of transcription, DNA repair
or apoptosis (Johnson and Walker, 1999). In addition to the
interaction between cyclin and Cdks, there are several levels of
regulation including cyclin-dependent kinase inhibitors (CdkIs)
and ubiquitin-mediated proteolysis which are also involved in
controlling the activity of Cdks during the cell cycle (Kastan and
Bartek, 2004).
Manipulation of the host cell cycle is a frequent strategy for
viruses to evade host cells, presumably in order to achieve a
cellular environment favorable for their replication (Nascimento
et al., 2012). Due to the complex and interactive nature of
intracellular signaling pathways in controlling cell division,
which could provide many opportunities for viral manipulation,
the important effect of viral regulation on cell cycle dynamics
are the consequences for driving neoplastic transformation. This
offers a rational approach to the control of virus causing cancers
(Gabrielli et al., 2012). The study of host evasion strategies
for cell cycle manipulation evolved by viruses will undoubtedly
reveal new control mechanisms and their corresponding cellular
signaling pathways.
Kaposi’s sarcoma-associated herpesvirus (KSHV), also known
as human herpesvirus type 8 (HHV-8), is a gamma-herpesvirus
associated with several human malignancies including Kaposi’s
sarcoma (KS), primary effusion lymphomas (PEL), and
multicentric Castleman’s disease (MCD) (Dupin et al., 1999).
As shown in Figure 1A, the KSHV genome is an approximately
140 kb long unique coding region (LUR) that is flanked by
multiple, non-coding terminal repeat (TR) units with high GC
content (Russo et al., 1996; Ohsaki and Ueda, 2012). The LUR
encodes about 90 open reading frames (ORFs), 12 microRNAs
and several ncRNAs (Russo et al., 1996; Toth et al., 2013).
Like all herpesviruses, KSHV exhibits two distinct phases of
infection: latency and lytic replication. In primary infection,
KSHV enters a latency whereby the viral genome circularizes and
exists as nuclear episome through multiple host cell divisions.
During latent infection, only a subset of viral genes including
latency-associated nuclear antigen (LANA, ORF73), v-Cyclin
(ORF72), v-FLIP (ORF71), and Kaposin (K12) are expressed
(Figure 1A). Upon stimulation such as chemical agents or
environmental stress, KSHV could be reactivated from latency to
lytic replication and in turn produce infectious virion progeny
(Yu et al., 1999; Davis et al., 2001).
LANA ENCODED BY KSHV IS A
MULTI-FUNCTIONAL ONCOPROTEIN
Many evidences have shown that KSHV establishes a stable
latent infection which plays an essential role in KSHV-
induced malignancies and pathogenesis (Dupin et al., 1999;
Katano et al., 2000; Parravicini et al., 2000). Serological
analysis of the infected cells by immunofluorescence and
immunohistochemistry indicated that LANA is one of only a
few latent proteins consistently present in all KSHV-infected
tumor cells of KS, PEL, and MCD (Dupin et al., 1999;
Katano et al., 2000; Parravicini et al., 2000). It has been well
demonstrated that LANA is a multi-functional protein with
approximately 1162 amino acids in length, through directly or
indirectly interacting with many other molecules in different
signaling pathways including apoptosis, cell proliferation and
gene transcription (Figure 1B). Many studies have shown that
LANA contains unique nuclear localization signal (NLS) and
is localized in the nuclei and interacts with host cellular DNA
and KSHV genome in a punctate pattern during interphase
and mitosis (Ballestas et al., 1999; Cotter and Robertson, 1999).
This indicates that LANA is a cell-cycle related protein. LANA
contains a large internal region of acidic and glutamine-rich
repeat, and separating the amino and carboxyl terminal region
of LANA, although it has been noted that the length of the
internal repeat region varies between different KSHV isolates
(Gao et al., 1999). LANA encodes various functional motifs
to specifically recruit different target molecules. For examples,
LANA has a chromosome-binding motif within 5–13 amino acids
to bind with histones H2A/H2B (Barbera et al., 2006), a motif
to recognize DNA sequence within the TR region of KSHV
(Srinivasan et al., 2004; Kelley-Clarke et al., 2009), a region for
LANA oligomerization (Komatsu et al., 2004), a SOCS-like box
motif to recruit EC5S (Elongin BC-Cullin5) ubiquitin complex
(Cai Q.-L. et al., 2006), a SIM motif to bind with SUMO molecules
(Cai et al., 2013), and so on. Interestingly, the phenomenon
that LANA drives transgenic mice developing splenic follicular
hyperplasia (Fakhari et al., 2006), and transforms primary REF
cells when conjunction with h-Ras (Radkov et al., 2000), as
well as LANA upregulates the transcriptional activity of human
telomerase promoter through interaction with Sp1 (Knight et al.,
2001; Verma et al., 2004), supporting the notion that LANA acts
as an oncoprotein to contribute to the pathogenesis of KSHV
infection. In regard to how LANA plays a critical role in KSHV
episome persistence, DNA replication and gene transcription,
as well as program switch of latency and lytic replication, two
reviews have been summarized recently (Ballestas and Kaye,
2011; Uppal et al., 2014). However, although it is clear that LANA
binds to nucleosomal proteins throughout the cell cycle, how
LANA associates with the regulators of cell cycle to driving cell
proliferation remains elusive. Here, we summarize and highlight
the recent progression of cell cycle regulatory functions of LANA.
LANA DEREGULATES CELLULAR
ONCOPROTEINS AND GROWTH
SUPPRESSORS
Both control of cell cycle checkpoints and inhibition of apoptosis
are hallmarks of tumor cell proliferation including KSHV-
infected KS and PEL cells. Many studies have shown that
LANA not only blocks tumor suppressor pathways, but also
enhances expression of oncogenes which involve in cell cycle
regulation, supporting the role of LANA in cell transformation
and growth. For examples, the inhibitors of DNA binding (Id)
have been demonstrated to involve in cell cycle regulation
through deregulating expression of p21 (Nickoloff et al., 2000).
Moreover, Id-1 could directly interact with the p16 promoter to
drive cell proliferation (Alani et al., 2001). The introduction of
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FIGURE 1 | (A) Schematic and location of the KSHV latent genes including miRNA cluster. Bottom: The major latency locus (ORF73/LANA, ORF72/v-Cyclin,
ORF71/vFLIP, and K12/Kaposin) of KSHV is shown in an enlarged view. Position of 12 pre-miRNA cluster is shown in red triangle. (B) The structure and functional
motifs of Latency-associated nuclear antigen (LANA). LANA consists of 1162 amino acids. Numbers indicate the amino acids (aa). Repetitive regions and key motif
of LANA are noted. P, Proline; DE, Aspartic acid and Glutamic acid; Q, Glutamine; L, Leucine; NLS, nuclear localized sequence; BC, Elongin B and C; Cul: Cullin5;
SIM, SUMO-interacting motif. The binding regions of LANA-associated cellular and viral proteins are listed at the bottom panel.
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LANA in endothelial cells dramatically increased Id-1 expression,
suggesting that LANA may drive cell proliferation by targeting
Id-1 expression (Tang et al., 2003). Many other oncoproteins
associated with prolonged cellular survival are also affected by
LANA. For examples, LANA activates telomerase expression
(Verma et al., 2004), stabilizes c-myc and HIF1α oncoproteins
and promotes its transcriptional activity (Cai Q. et al., 2006;
Bubman et al., 2007; Cai et al., 2007; Liu et al., 2007b), increases
level of ICN in Notch signaling pathway (Lan et al., 2007),
upregulates expression of Aurora Kinase (Cai et al., 2012), as
well as associates with and upregulates Pim1 kinase activity (Bajaj
et al., 2006; Cheng et al., 2009). On the other hand, LANA also
functions as a component of E3 ubiquitin ligase to target tumor
suppressors like p53 and VHL for degradation, which creates
a favorable environment for cell growth. LANA also affects the
tumor suppressor p73 stability and subnuclear localization to
contribute to the survival of PEL cells (Santag et al., 2013). Due
to activation of TGF-β signaling pathway in many cell types
results in inhibition of cell growth and induction of apoptosis,
LANA suppresses the promoter of TGF-β type II receptor (TβRII)
through epigenetic silencing (Di Bartolo et al., 2008), which may
lead to cell proliferation by activation of c-myc, p15, and Cdc25A.
To further explore the role of LANA on cell cycle regulation, our
recent studies revealed that LANA upregulates transcription of
59 of 116 cell-cycle genes (including CDK4, Cdc25A/C, BAX, and
BCL2), and only downregulates eight genes (Figure 2) (Cai et al.,
2010; Gan et al., 2015). This indicates that LANA plays a positive
instead of negative regulation on process of cell progression.
LANA MANIPULATES G1-S
PROGRESSION
Upon growth factors such as epidermal growth factor (EGF) and
insulin-like growth factor (IGF), the sequential activation of the
two kinase complexes, Cdk4/6-cyclin D, and Cdk2-cyclin E, is the
key event that leads to cell cycle progression (Figure 3). These
activated complexes could phosphorylate tumor suppressor
retinoblastoma (RB), and in turn dissociate E2F from RB and
accumulate E2F. In the LANA-expressing cells, LANA interacts
with RB and enhances the transcriptional activation of E2F-
responsive genes (Hume and Kalejta, 2009). In addition, LANA
has also been shown to interact with glycogen synthase kinase
(GSK-3β), a kinase involved in phosphorylation and subsequent
degradation of many cell-cycle regulators including c-Myc and
Cyclin D (Fujimuro et al., 2003; Bubman et al., 2007; Liu et al.,
2007a,b). Recent studies showed that the interaction of GSK-3
with LANA could lead to the accumulated expression of iASPP
and in turn degradation of p53 for cell growth (Woodard et al.,
2015). Our previous studies further demonstrated that p53 can
be degraded by LANA-mediated recruitment of the cellular EC5S
(Elongin BC-Cullin 5-Rbx1) ubiquitin complex (Cai Q.-L. et al.,
2006), as well as involvement of the Serine/Threonine oncogenic
kinase Aurora A (Cai et al., 2012).
In response to DNA damage, entry of cells into S
phase is prevented by activation of the two transducing
kinases, ATM/ATR and Chk1/Chk2, and followed by Cdc25A
phosphorylation and p53 activation. Phosphorylated Cdc25A
pathway has a faster inhibitory impact on the cell cycle
progression (Lukas et al., 2004). In contrast, both Chk1/Chk2
and ATM/ATR-mediated phosphorylation on Serine 15 of p53
signaling can further prolong G1 arrest. Recent studies showed
that LANA directly interacts with Chk2 to block ATM/ATR-
mediated apoptosis and potential activation of Cdc25A (Kumar
et al., 2014). Meanwhile, Mdm2 (the negative regulator of p53)
is inactivated by ATM/ATR, and association of p53 with p300
results in increased transcriptional activity of p300. The p53-
mediated induction of downstream genes including p21 blocks
the G1/S progression which promoted by Cdk2-cyclin E kinase
expression. The inhibitors of p53-MdM2 interactions including
nutlin-3 interfere with the formation of Mdm2-p53-LANA
complex and cause G1 arrest and apoptosis of PEL cells (Petre
et al., 2007; Sarek et al., 2007; Ye et al., 2012), further supporting
the notion that modulation of p53-dependent pathways by LANA
is critical for KSHV to prevent cell cycle arrest and apoptosis.
In addition, LANA has been shown to bind and block
p53-mediated transcriptional activity and in turn inhibit p53-
induced cell apoptosis (Friborg et al., 1999; Si and Robertson,
2006; Lu et al., 2009). It has been demonstrated that LANA
can also positively regulate cell cycle-dependent promoters, and
promote the G1/S transition of cells by overcoming the serum
starvation, overexpression of cyclin-dependent kinase inhibitor
p16, or BRD4 and BRD2/RING3-induced G1 cell cycle arrest
(Platt et al., 1999; Direkze and Laman, 2004; An et al., 2005;
Viejo-Borbolla et al., 2005; Ottinger et al., 2006). Moreover,
Disruption of Annexin A2 with LANA results in downregulation
of cell cycle-asociated CDK6, cyclin D, E, and A protein,
indicating that LANA upregulates cyclin D, E, and A proteins
during the G1/S phase of cell cycle (Paudel et al., 2012a). In
consistent, to maintain the viral genome in each cell cycle, LANA
recruits proliferating cell nuclear antigen (PCNA) via Bub1 and
replication factor C (RFC) to initiate DNA replication of viral
genome during S phase, and enhances survival of KSHV-infected
cells in response to UV-induced DNA damage (Sun et al., 2014,
2015). In addition, to enhance the survival of KSHV-infected
cells, LANA upregulates the angiogenic multifunctional protein
angiongenin (ANG) (Sadagopan et al., 2009). Further studies
showed that LANA interacts with ANG/annexin A2 to contribute
to the binding of LANA with p53 (Paudel et al., 2012a,b).
LANA EFFICIENTLY DISRUPTS THE
BLOCK TO THE G2/M CHECKPOINT
DNA damage is a common phenomenon through exposure
to a variety of environmental stresses, including abnormally
low oxygen, or nutrients. Before cells enter mitosis, the G2/M
checkpoint responds directly to DNA damage by repairing DNA
breaks or alternately by holding cell cycle progression and/or
by undergoing programmed cell death. The key target of G2
arrest is the mitosis promoting complex Cdk1-cyclin B. In
response to different type of DNA damage, the ATM-Chk2 or
the ATR-Chk1 signal pathway is activated to arrest the cell in G2
phase by blocking activation of Cdk1-Cyclin B or inhibition of
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FIGURE 2 | Hierarchical clustering of genes profiling related to cell cycle in BJAB cells with LANA-RFP stable expression or RFP vector alone. Data
analysis revealed that 67 out of 116 genes are changed by over twofold in their expression in the presence of LANA.
Cdc25B/C phosphatase (an enzyme normally activates Cdk1 at
G2/M transition). The increased phosphorylation of Cdc25B/C
is observed during G2 arrest. Both Chk1 and Chk2 kinase are
able to phosphorylate Cdc25B/C in response to DNA damage.
The ATM/ATR kinase not only activates Chk1 and Chk2 but
also phosphorylates p53 on its serine 15. Phosphorylation of p53
prevents p53 binding with MdM2, thereby stabilizing p53. The
stabilized p53 in turn up-regulates the Cdk inhibitor p21 at the
G1 checkpoint, which eventually leads to cell arrest or apoptosis.
Although no literatures reported that LANA could directly
target Cdc25B/C or Cdk1-cyclin B complex, many molecules
[including p73 (Santag et al., 2013), ANG (Sadagopan et al.,
2009), Mdm2 (Sarek et al., 2007), and GSK-3 (Woodard et al.,
2015)] have been shown to interaction with LANA for blocking
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FIGURE 3 | Latency-associated nuclear antigen-mediated deregulation of cell cycle. LANA associates with many cellular proteins including GSK-3, c-Myc,
Chk2, BRD4, and BRD2/RING3, to activate Cyclin D1-CDK4/6 and Cyclin E-CDK2 complex, which results in the hyperphosphorylation form of retinoblastoma
protein (RB). Hypersphophorylation of RB prevents its interaction with E2F, and releases E2F to activate expression of genes required for entry into the S phase.
LANA also interacts with RB to facilitate G1/S phase transition. On the other hand, LANA not only recruits E3-ligase complex (including Elongin BC-Cullin 5, EC5S)
or MDM2 to target p53 for ubiquitin-mediated degradation, but also associates with many p53-associated pathway regulators including p73, iASPP, and Chk2 to
induce Cyclin B-CDK1 complex for driving G2/M phase transition. The positive and negative regulation by LANA is shown by solid orange line. The cellular signaling
pathway blocked by LANA is indicated by dot line.
p53-mediated apoptosis during G2/M checkpoint. Recent studies
showed that LANA upregulates the expression of survivin, and
recruits Aurora kinase B to induce phosphorylation of Survivin
at Tyrosine 34 (Lu et al., 2009, 2014), which potentially drive host
cell proliferation during mitosis. Moreover, in human B cells, it
has been demonstrated that LANA directly interacts with Chk2
(the ATM/ATR signaling effector) to relieve the nocodazole-
induced G2/M checkpoint arrest (Kumar et al., 2014). This
indicates that LANA also involve in the deregulation of G2/M
checkpoint during cell progression (Figure 3).
FUTURE PERSPECTIVE
In the view of the facts that in addition to promoting cell cycle
arrest, most members of herpesviruses family also activate several
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factors to induce cell cycle progression. It is of importance
and complex to elucidate how KSHV-encoded LANA balances
the interaction between herpesvirus and cell cycle regulatory
mechanisms. In the past two decades, numerous studies have
shown that LANA is a multifunctional oncoprotein ubiquitously
expressed in the KSHV-infected cells, and modulates various
cellular pathways to drive cell proliferation. To seek the
chemical compounds to efficiently block the KSHV-driven cell
proliferation and its associated cancers, Gao and Schulz groups
have shown that the small-molecule inhibitors Nutlin-3 and
RETRA, which disrupt the interaction of p53 and p73 with
MDM2, are efficient to individually induce apoptotic cell death
in a p53 and p73-dependent manner (Ye et al., 2012; Santag
et al., 2013). Glycyrrhizic acid (GA), a triterpenoid compound
shown to inhibit the lytic replication of herpesviruses, is able to
reduce the expression of LANA and leads to G1 cell cycle arrest
and p53-mediated apoptosis of PEL cells (Curreli et al., 2005).
Gamma-secretase inhibitor targeting LANA-mediated Notch
pathway also inhibits cell growth and death (Liu et al., 2010).
Taken together, these studies now clearly show that in addition
to regulating transcription, chromatin remodeling, episome
maintenance, DNA replication, and control of latency and lytic
reactivation, LANA also plays a critical role in KSHV-mediated
tumorigenesis by regulating cell cycle machinery. Understanding
the role of LANA in regulation of cell proliferation, particularly
on regulation of episome replication and segregation during
cell cycle, will lead to a better understanding of cellular growth
control processes, which will open an opportunity target to
prevent and treat KSHV-associated malignancies.
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